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Post-transcriptional gene regulation plays an important role in controlling 
gene expression patterns in mammalian cells. CUG-binding and Embryonic Lethal 
vision-type RNA-binding protein 3 (ETR)-like Factor (CELF1), also known as 
CUGBP1, is a RNA-binding protein involved in post-transcriptional gene regulation 
through nuclear (alternative splicing) and cytoplasmic (mRNA turnover and 
translation) mRNA processing events. Primarily, CELF1 is known for its contribution 
to the development of myotonic dystrophy (DM1). But, published observations from 
our laboratory and others determined that CELF1 is overexpressed in head and 
neck squamous cell carcinoma (HNSCC) as well as multiple other cancers. 
Unpublished proteomic pulsed-stable isotope labeling by amino acids in cell culture 
(pSILAC) from our laboratory, has identified approximately putative 1350 CELF1 
target proteins were controlled at the mRNA translation level in UM74B oral cancer 
cells. The pSILAC data and subsequent ribosome profiling validation experiments 
revealed that the protein expression of MARCKS (Myrisoylated alanine-rich kinase C 
substrate) is significantly reduced upon CELF1 knockdown in comparison to control 
oral cancer cells. MARCKS is known to play an important role in cell shape, cell 
motility, secretion, transmembrane transport, and regulation of the cell cycle in 
cancer cells. We have determined that MARKCS protein is overexpressed in 
HNSCC cell lines compared to primary normal oral keratinocytes. Moreover, CELF1 
directly controls the expression of MARCKS, but its mRNA levels remain unchanged 
in oral cancer cells. CELF1 ribonucleoprotien immunoprecipitation (RNP-IP) 
experiments determined that MARCKS mRNA is directly associated with CELF1. 
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The cell migratory role of MARCKS was evaluated by a scratch wound healing 
assay and transwell migration assay. Depletion of CELF1 and MARCKS 
independently resulted in reduction of cell migration. Moreover, overexpression of 
CELF1 in normal non-malignant human oral keratinocyte cells resulted in 
overexpression of MARCKS and enhanced cell migration. Finally, shRNA-mediated 
reduction of CELF1 in association with exogenously expressed MARCKS in oral 
cancer cells, we were able to rescue the CELF1-mediated cell migration phenotype. 
In conclusion, our results demonstrate that CELF1 controls cell migration through 
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Overview of HNSCC  
Head and neck squamous cell carcinoma (HNSCC) represents a wide- 
variety of tumors that arise from base of the skull to the clavicles (1). HNSCC 
anatomic sites include: orbits, nasopharynx, oral cavity, oropharynx, hypopharynx, 
sinuses and larynx (1). HNSCC is considered to be the 6th most common cancer 
worldwide, with 400,000 or more new cases registered annually and of those cases, 
only 40-50% will survive within next 5 years (2). In the United States alone more 
than 42,000 cases and 8,300 deaths were predicted for this disease in 2014 (3).  
Factors such as tobacco carcinogens along with alcohol consumption have shown to 
be a major risk factor for HNSCC in Western countries (4). In the past few decades, 
up-rise of sexually transmitted infection, human papillomaviruses (HPV), among 
young people has emerged as a major risk factor (5, 6) for oral carcinogenesis. But 
recent advances in early diagnosis through three-dimensional imaging, such as 
computed tomography (CT scans) and magnetic resonance imaging (MRI) have 
allowed for better staging, and treatment planning for HNSCC patients (1).  
Although, there have been many advances in HNSCC treatment, the overall 
survival rate of HNSCC patients only improved marginally over the past 30 years (2).  
Currently, nonselective treatments such as: surgery, radiation, and chemotherapy 
are being implemented for HNSCC patients (2). These nonselective treatments have 
high systemic toxicities and associated morbidity and mortality (2). Thus, 
understanding the molecular mechanisms and underlying cause of HNSCC will aid 
in the development of more selective and effective cancer treatment options for 
HNSCC patients.  
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Post-transcriptional control of gene expression 
The central dogma of the cell states that DNA is transcribed into RNA, which 
is subsequently translated into protein (7). The complexity of the human proteome is 
derived from the control of post-transcriptional gene regulation. Disruption of post-
transcriptional gene regulation often leads to cancer predisposition (8-10), viral 
infections (11-13) and neuromuscular disorders (14, 15). Post-transcriptional control 
of gene expression involves several steps, including mRNA processing, transport, 
stability and translation. The mRNA stability or turnover is either deadenylation-
dependent or independent in mammalian cells (16) and these complex regulatory 
pathways control more than 50% of gene expression patterns. However, in general, 
the deadenylation-dependent mRNA decay process dominates the mRNA 
degradation process due to fact that most of the poly-A tail containing mRNAs 
undergo nuclear export and cytoplasmic mRNA translation and turnover (16).  
 Messenger RNA turnover rates determine the life span of an mRNA molecule. 
Messenger RNAs with fast turnover rates are considered short-lived mRNAs, 
conversely, long-lived mRNAs have slower turnover rates (17). Thus, in the context 
of changing environmental cues, these different mRNA turnover rates contribute to 
cellular gene expression. For example, vascular endothelial cells produce few or no 
growth factors, ILs (interleukins), or adhesion molecules, but with treatment of IL-1, 
gro-α mRNA is specifically stabilized (18). On the contrary, glucocorticoids, like 
estrogen have been shown to destabilize IL-1β (19), interferon (20) and collagen 
(21) mRNAs. Finally, regulation of mRNA half-life can occur through association of 
protein trans-acting factors and nucleotide cis-elements (22). The cis-elements such 
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as TG-rich motifs (TTCTG and TGTT) are located in the 3ʹ′ UTR and can promote 
mRNA decay and/or stability with the help of trans-acting factors such as RNA-
binding proteins (RBPs) and noncoding RNAs (22, 23). High-throughput analysis 
messenger ribonucleoproteins (mRNPs) from mammalian cells showed that RBPs 
associated with unique subset of mRNAs to coordinately regulate their localization, 
translation and/or degradation (22, 24-27).  
 Deadenylation-dependent mRNA decay is the major pathway in mammalian 
cells. Most mammalian mRNAs are polyadenylated in the nucleus undergoes 
nuclear mRNA processing, transport into the cytoplasm, and subjected to translation 
and turnover. In the deadenylation-dependent mRNA decay pathway, one or a 
combination of deadenylases (Pan2-Pan3, Ccr4-Not and poly(A)-specific 
exoribonuclease (PARN)) removes the poly(A) tail located in the 3ʹ′ UTR of mRNAs 
(28, 29). Following deadenylation, exonucleases proceed with mRNA degradation in 
a 5ʹ′-3ʹ′ or 3ʹ′-5ʹ′ direction. Another pathway that controls mRNA decay, is the non-
sense mediated decay pathway (NMD). NMD is a mRNA surveillance pathway that 
targets mRNAs with premature stop codons (16). Messenger RNA surveillance is 
the process of ensuring the destruction of mRNA that would otherwise produce 
nonfunctional protein due to either mutations in a gene, errors in pre-mRNA splicing 
that retain introns or nonproductive chromosomal rearrangements (30). An additional 
mRNA decay pathway that has been identified is called nonstop mRNA decay 
(NSD). This pathway has been proposed recently and illustrated that the translation 
of mRNAs that lacks the stop codon allows ribosomes to translate to the end of the 
3ʹ′ UTR, leading to mRNA degradation (31).  
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GRE-Mediated mRNA Decay 
 During the investigation of T cell activation, a genome-wide database of 
mRNA half-lives has been established (32). The database contains many transcripts 
that possess both AU-rich elements (AREs) and GU-rich elements (GREs), and their 
half-lives under the activation of T cells. This observation led researchers to identify 
a canonical sequence in the form of UGUUUGUUUGU; which associates with the 
cytoplasmic protein CUGBP1 and Etr3 like Factor 1 (CELF1) (33). Further 
investigation uncovered a recruitment of PARN by CELF1 for decay of GRE 
containing mRNA (34). This mRNA decay mechanism is consistent with the 
observations made in vitro that show CELF1 association with mRNA correlates with 
enhanced deadenylation in both HeLa cells (35) and Xenopus (36).  
CUG-binding and Embryonic Lethal abnormal vision-type RNA-binding protein 
3 (ETR-3)-like Factor (CELF) 
 The CELF proteins are a family of RNA binding proteins that are known to 
play an important role in post-transcriptional gene regulation (37, 38). In humans and 
mice, there have been six members identified in the CELF family: CELF1-6, and 
CELF1 and CELF2 proteins are expressed ubiquitously and play important role in 
embryogenesis (39-43), CELF3-6 are expressed in adult tissues and mostly found in 
the nervous system (44, 45). CELF1 is well-studied protein in myotonic dystrophy, 
but its cancer biological role has not been described before. Hence, I plan to study in 
this thesis to decipher CELF1’s cancer biological role in oral cancer cells.  
 CELF1 was first shown to be involved in alternative splicing of the mRNAs in 
the nucleus (46-48), and further studies revealed that CELF1 localized in the 
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cytoplasm (49), indicating that CELF1 could be involved in pre-mRNA splicing, 
turnover or translation. CELF1 was first identified as EDEN-BP (Embryonic 
Deadenylation Element-Binding Protein) in the Xenopus Laevis (36). EDEN-BP is a 
homolog of CELF1 and determined to cause a rapid decay of mRNAs. But, later it 
was determined that mRNAs that are being degraded by EDEN-BP occurred 
through binding to U/G rich sequences in 3ʹ′ UTR. The binding triggered 
deadenylation and translational repression of mRNA by recruitment of poly(A) 
ribonuclease (35).  
In Xenopus, CELF1 was identified as a translational repressor by binding to a 
specific motif in the 3ʹ′ UTR of its targets mRNAs. These motifs were termed the 
“Embryonic Deadenylation Element” (EDEN) motifs. The binding triggers rapid 
deadenylation and therefore, the translation is inhibited and leads to degradation of 
the bound mRNA. Furthermore, human and Xenopus CELF1 have very high degree 
of sequence conservation and exactly 88% of the sequences are identical and the 
conserved. Due to similarities between these two proteins, they can compensate for 
one another and CELF1 was considered as a deadenylation factor (50). Based on 
the sequence similarities EDEN and CELF1 presumed to recognize similar subsets 
of mRNA targets (51). Overexpression of CELF1 causes muscular disease DM1 by 
imperfectly targeting its mRNAs leading to those encoding proteins misregultion in 
muscular functions (52-55).  
Structure of CELF proteins 
CELF proteins contain highly conserved RNA-Recognition Motifs (RRM), of 
which, two RRMs are located at the N-terminus and third RRM located at the C-
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terminus, separated by the divergent linker domain. Furthermore, the RRMs have 
RNA binding activity and it is proposed that the divergent domain is an important site 
for functional regulation. This highly conserved family of proteins regulates the 
developmental processes and gene expression at post-transcriptional levels in 
Gallus, Zebrafish, Drosophila and C. elegans (36, 37, 56-59).  
Protein domains of CELF1  
The human CELF1 protein has the basic arrangement of three RRMs like 
other CELF family of proteins. The CELF1 is a 486 amino acid protein with a total 
mass of 52.1kDa. The RRMs are very important for CELF1 binding to its target 
mRNAs. There are multiple reports indicated that CELF1 targets mRNAs through 
AU-rich or GU-rich sequences (60, 61). Nuclear magnetic resonance spectroscopy 
(NMR) studies revealed that both the RRM1 and the RRM2 domains of CELF1 bind 
to 12-nucleotide targeted RNAs containing two UUGUU motifs. Moreover, binding of 
both RRM-1 and -2 domains have higher affinity compared to the binding of 
individual domains separately, suggesting a cooperative binding between these 
RRMs (62, 63). Further crystallographic studies showed that both RRM-1 and RRM-
2 binds to GRE-RNAs, and RRM-1 is essential for crystal-packing interactions (64). 
Utilizing an NMR approach, RRM-3 has also been shown to bind specifically to UGU 
trinucleotide segment of bound (UG)3 RNA. The recognition is through stacking and 
hydrogen bonding interactions within a pocket formed by the beta-sheet and the 
conserved N-terminal of RRM3 (60). 
 NMR studies along with yeast three-hybrid system, deletion and mutation 
analysis have been essential in understanding the interaction of various CELF1 
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domains with its target RNA. In an yeast three-hybrid system, deletion/mutation of 
RRM-1 or RRM-2 did not affect CELF1 binding to GU-rich RNAs, whereas RRM-3 
has the ability to recognize GU-repeats more strongly than RRM-1 or RRM-2 (65).  
Additionally, combination of CELF1’s divergent domain and RRM-3 known to poorly 
recognize the G/C-rich sequence of Cyclin D1 in the 5ʹ′ UTR (66).  
Mechanism of CELF1 binding to Target mRNAs 
CELF1’s sequence recognition 
Isolation and characterization of CELF1 and CELF2 demonstrated that they 
are novel heterogeneous nuclear ribonucleoproteins (hnRNPs). CELF1 has been 
shown to interact with two distinct types of RNA sequences: UG rich elements (67) 
and CUG repeats (68). An in vitro study by Timchenko et.al, showed that binding of 
CELF1 to the 3ʹ′ UTR of mytonic protein kinase mRNA occurred due to the presence 
of (CUG)8 sequences (52, 54). Further SELEX (systemic evolution of ligands 
exponential enrichment) (69), SPR (surface plasmon resonance) (65) and yeast 
three-hybrid systems (67) revealed that CELF1 preferentially binds to GU-rich 
sequences (33, 70). These observations were confirmed in C2C12 cells utilizing 
RNA immunoprecipitation (RNA-IP) followed by microarray (RIP-Chip) analysis (71).  
In Xenopus, EDEN-BP orthologs of CELF1 appears to also bind to GU-rich 
mRNA sequences, which contain the sequence (UGUA)12 and function as a 
deadenylation signal in embryos after fertilization and deletion of EDEN-BP totally 
abolished EDEN mediated deadenylation activity (36, 50). In Drosophila, the CELF1 
ortholog is Bru-3 and in Xenopus, the CELF1 ortholog is EDEN-BP; in both 
organisms CELF1 specifically bind to the sequence of (UG)15 repeats (37). In 
9	  
	  
Zebrafish, a protein called Brul, which is 81% identical to EDEN-BP, preferentially 
binds to GU-rich mRNAs (48). Furthermore, in C. elegans the protein ETR-1 (ELAV- 
type RNA Binding Protein 1) is also a homolog of human CELF1. The reduction of 
ETR-1 caused failure of embryos to elongate and subsequent paralysis caused 
embryonic lethality (57). Interestingly, not only GU-rich sequences are required, but 
adjacent sequence elements are also important for assembly of CELF1 protein on 
RNA by allowing optimal secondary structure to facilitate the formation of RNA-
binding protein complexes (72, 73). Findings in Xenopus and C. elegans models 
suggest that CELF1 homologs are critical for muscle development. Dysregulation of 
CELF1 is involved in the pathogenesis of the human neuromuscular disease, 
myotonic dystrophy type 1 (DM1) (74). CELF1 has also been shown to be a mRNA 
decay regulator in muscle tissue through GRE element recognition, therefore, 
dysregulated CELF1 mediated mRNA decay may be involved in pathogenesis of 
DM1 (74). In addition to conservation of biomedical mechanisms of CELF1-GRE 
regulation, these results also suggest that CELF1-GRE mediated regulation is 
preserved over evolution at the organismal level and regulate specific aspects of 
developmental programs. 
Dimerization of CELF1 
In Xenopus, EDEN-BP (homolog of CELF1) has been reported to undergo 
dimerization in a yeast two-hybrid assay, and the dimerization may have a role in 
RNA recognition (75, 76). However, no human CELF1 dimerization has been 
reported in the literature. The yeast two-hybrid observation does raise the question 
of whether dimerization is due to the formation of a true dimer or whether two CELF1 
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proteins dimerize as a result of binding to one RNA molecule, but this observation 
needs further investigation.   
Phosphorylated CELF1 and RNA metabolism  
 CELF1 was considered as a phosphoprotein, and protein kinase C (PKC) can 
stabilize CELF1 by hyper-phosphorylating the protein in DM1 cells (49). 
Furthermore, it has been shown that hyper-phosphorylated CELF1 is unable to 
degrade TNF-α in DM1, suggesting that phosphorylation may interfere with CELF1 
mRNA binding and decay (77).  The support for a pathogenic role of CELF1 hyper-
phosphorylation comes from a DM1 transgenic mouse model (78). Interestingly, 
mice treated with the specific inhibitor of the PKC resulted in cardiac abnormalities 
associated with the disease phenotype. 
The CELF1 protein is also predicted to have phosphorylation sites for several 
phosphatases (79). Therefore, the phosphorylation of CELF1 has been suggested to 
play an important role in regulating its RNA binding preference, and interaction with 
other proteins (80-82). Phosphorylation has been shown to occur at Ser28 and 
Ser302; and demonstrated that phosphorylation affects the RNA binding of CELF1 
(80). Akt kinase has been shown to phosphorylate CELF1 at the Ser28 residue and 
this specific residue has been shown to affect translation during differentiation of 
normal muscle myoblasts. Additionally, it has also been proposed that 
phosphorylation of CELF1 at Ser28 serves as a switch between binding to U/G- rich 
and C/G-rich sequences. For example, non-phosphorylated form of CELF1 binds to 
U/G- rich sequences but upon phosphorylation, CELF1 binds to C/G-rich sequences. 
Another example, CELF1 binds to the cyclin D1 mRNA upon the phosphomimetic 
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mutation S28D (66). Finally, phosphorylation of CELF1 at Ser302 alters its RNA-
binding activity. For example, cyclin D3-Cdk4/6 complex phosphorylates CELF1 at 
Ser302, and effects the binding specificity of CELF1 to its targeted RNA (83). All 
together, these observations indicate that CELF1 functions in many aspects and in 
multiple disease states through phosphorylation.  
CELF1 play a role in pre-mRNA splicing  
Diversity within RNA transcripts and protein can be generated through pre-
mRNA alternative splicing; and it has been determined that 90% of human genes 
produce alternatively spliced transcripts (84, 85). Alignment of the genomic regions 
adjacent to mammalian intron-exon splice sites, identified TG –rich motifs (TTCTG 
and TGTT) as conserved cis-elements that are associated with alternative splicing 
(86, 87). These identified C/UG-rich templates served as binding sites for CELF 
proteins, which can either activate or suppress the splicing of pre-mRNA targets 
depending upon the genomic environment (88).  
In DM1, aberrant gain of CELF1 function and simultaneous loss of the 
splicing factor MBNL1 has been shown (89). Moreover, CELF1 and MBNL1 have 
opposite effects on exon/intron inclusion upon binding to specific sequences. The 
opposite effect is due to mis-splicing of various crucial genes (74). For example, 
minigene reporter system that contain alternative splice sites for CELF1 to identify 
pre-mRNA targets, these targets includes but not limited to cardiac troponin T (55), 
insulin receptor (90), and chloride channel 1 (46, 91). This system has shown that 
either loss or gain of these regulatory proteins occurs through pre-mRNA splicing 
events. Further studies have used cultured cells with transiently transfected 
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minigenes and results have identified a number of alternative gene regions that are 
regulated by CELF1 and other RBPs (46, 55, 60, 90-99).  
 An additional role of CELF1 mediated alternative splicing has emerged from 
early developmental studies that used transgenic CELF1 deficient mice which 
showed altered regulation of fetal to adult splicing pattern of several skeletal muscle 
transcripts (91, 100). In order to determine the global role of CELF1 in fetal-to-adult 
transition, mouse models have been used (89). In particular, splicing microarrays 
were utilized and demonstrated that half of the transcripts that underwent fetal-to-
adult alternative splicing transitions occurred in the heart tissue due to 
overexpression of CELF1, which resulted in alternative splicing pattern of transcripts 
(89). Furthermore, in order to study CELF1-specific alternative splicing, a 
development of dominant negative and tissue specific transgenic mice was ideal for 
in vivo (92, 95, 100, 101). For example, under the control of a cardiac muscle-
specific promoter expressing dominant negative CELF1 (DNΔCELF1) showed 
development of dilated cardiomyopathy and cardiac dysfunction over time (92).  
CELF1 as an mRNA Translation Regulator 
 Protein translation is an important part of post-transcriptional control of gene 
expression that is regulated and adapted to various environmental and 
developmental changes. CELF1 at some extend activates (102) and inhibits (83, 
103) the translation of various mRNAs that are involved in multiple developmental 
stages. Some homologs of CELF1 have also been shown to regulate translation. For 
example, in the Drosophila oocyte, when Bruno, a homolog of CELF1, binds to 
Bruno response elements (BREs) within the 3ʹ′ UTR of oskar mRNA, protein 
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translation was inhibited. Additionally, Bru-3 (another CELF1 ortholog) bound to the 
3ʹ′ UTR GU-rich sequence of gurken, cyclin A and oskar mRNA also lead to inhibition 
of translation (56). The proposed translation inhibition mechanism of Bru-3 is 
mediated through formation of Bru-3/eIFA4E/5ʹ′-cap complex at various stages of 
embryo development (104).  
 In mammalian cells, CELF1 has also been identified as a translational 
regulator of selective mRNAs. For example, CELF1 has been demonstrated to 
promote the translation of alternative isoforms of the transcription factor 
CCAAT/enhancer-binding protein (CEBPβ) (68, 105, 106). This regulation was first 
described in a rat model of partial hepatectomy. In this model, partial hepatecomy 
caused CELF1 phosphorylation, which led to formation of a CELF1 and eIF2 
(eukaryotic initiation factor 2) complex. This complex initiated translation of the liver 
enriched inhibitor protein (LIP), an isoform of CCAAT/enhancer-binding protein (82). 
The confirmation of this experiment was demonstrated in liver cells. Additionally, it 
was shown that CELF1 goes through hyper-phosphorylation during normal aging via 
the GSK3beta-cyclin D3-cdk4 kinase pathway (107). In an age-associated model, 
just like the partial hepatectomy model, the cdk4-mediated hyper-phosphorylation of 
CELF1 also induced the CELF1-eIF2 complex formation (80). In addition, in a rat 
aging model, phosphorylation of CELF1 caused its interaction with a GC-rich 
sequence in the 5ʹ′ UTR of p21 mRNA inhibiting its translation and senescence in 
fibroblasts (108). In myocytes, stabilized p21 mRNA was observed in stress 
granules. However, only in late senescence did p21 localize in stress granules which 
interfere with its translation (109). Furthermore, under normal muscle cell 
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differentiation, CELF1 increased the translation of p21 (110), and Mef2a29 (111) via 
direct interaction with (GC)n repeats in the 5ʹ′ UTR. Additionally, binding of CELF1 to 
the 3ʹ′ UTR of the serine hydroxymethyltransferase (SHMT) mRNA (112, 113) and 
cyclin dependent kinase inhibitor p27 (kip1) (114), found to regulate translation 
activation of an internal ribosome entry site (IRES). These studies suggested 
CELF1’s role in IRES mediated initiation of mRNA translation. Fox J. et.al, have 
shown that IRES translation occurs through the formation of CELF1/hnRNPH 
complex, which promotes circularization of RNA transcripts by interaction of 5ʹ′/3ʹ′ 
ends (112).  
Taken together, these data suggest that CELF1 mediates translational 
regulation through G- and C-rich motifs and other various motifs in the 5ʹ′ UTR, 
whereas CELF1 mediated splicing and degradation affects occur through G- and U-
rich motifs in introns and the 3ʹ′ UTR. However, a global analysis of CELF1-mediated 
translational regulation remains to be determined. Thus, our interest remains to 
investigate CELF1 mediated translation in oral cancer cells. 
Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) 
In 1982, MARCKS was first identified as an 80kDa protein (115) and that is 
expressed in neural and central nervous system (CNS) tissues (116, 117), skeletal 
muscle (118), connective tissue (119) and leukocytes (120-123). MARCKS has been 
characterized and shown to be present in mammalians and non-mammalian 
species. The MARCKS protein only varies slightly among various species due to the 
conserved domains (116, 124-126). The MARCKS gene itself contains three-
conserved domains such as, mristoylated amino-terminal domain, MARCKS 
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homology domain 2 (MH2) and phospho-site domain (PSD). The PSD site serves as 
the phosphorylation site for PKC (127, 128) and the MH2 domain contains an intron-
splice site, but no known function has been demonstrated (127). 
 In resting cells, MARCKS is anchored to cellular membranes by its 
myristoylation motif and electrostatic interaction between the amino acids of the PSD 
and the acidic phospholipid bilayer, which is enriched in phosphatidylserine and PIP2 
(129, 130). MARCKS has been shown to be myristoylated post-transcriptionally, and 
an addition of myristoyl moiety (C14 saturated fatty acid) to the amino-terminal 
glycine residue. The myristoyl moiety allows MARCKS to insert itself hydrophobically 
into the phospholipid bilayer of the plasma membrane (118, 127, 130-135).  A 
combination of myristoylation and electrostatic interaction helps MARCKS anchor 
itself to cellular membranes and does so in an independent manner (132, 133, 136, 
137).  Furthermore, upon MARCKS phosphorylation, negative charges get 
incorporated into the PSD, resulting in the weakening of the electrostatic interactions 
between MARCKS and the phospholipid bilayer. This weakening causes MARCKS 
to completely dissociate from cellular membranes resulting in cytosolic localization 
(118, 132, 133, 135). This mechanism has been termed the “myristoyl-electrostatic 
switch” mechanism (136) and has been presumed to play a role in cell migration. 
Function of phosphorylated MARCKS  
 Initially, MARCKS was described as a substrate of PKC, which can 
phosphorylate MARCKS, either directly or indirectly. It has been shown in a rat 
model that that PKS and the PKC-related kinase 1 (PPK1) can phosphorylate 
Ser152, Ser156, and Ser163 of MARKCS within PSD. Additionally, G protein 
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coupled receptor signaling (GPCRs) and receptor tyrosine kinase (RTK) can activate 
PKC; in turn PLC cleaves PIP2 into inositol 1,4,5-triphosphate (IP3) and diacyl 
glycerol (DAG). DAG is stationed in the plasma membrane and IP3 opens calcium 
channels in the endoplasmic reticulum (138). Opening of calcium channels 
increases intracellular calcium concentrations. Interestingly, calcium is known to 
activate many isoforms of PKC. For example, conventional PKCs (α, βI, βII, γ) 
isoforms require DAG and Ca2+; novel PKCs (δ, ε, θ, η) isoforms only require DAG; 
and atypical PKCs (ζ, ι, λ), do not require DAG or Ca2+ (138). Phosphorylation of 
MARCKS has been shown to occur by both novel PKCs (ε, δ, θ) and classical PKCs 
(α, βII) (118, 139-141). Furthermore, MARCKS phosphorylation through PKC causes 
MARCKS to localize from cellular membranes to cytosol (142). Using a rat model, 
residue Ser152 of MARCKS shown to be phosphorylated through PKC activation 
and PKC has been shown to control the regulation of MARCKS ability to bind 
phosphatidylserine on the plasma membrane (143).  
In contrast, it has been shown that upon inhibition of the Rho-associated 
kinase (ROCK) signaling pathway and treatment of LPA leads to human MARCKS 
phosphorylation at Ser159 (Ser152 in mice), thus depicting an example of MARCKS 
indirect phosphorylation by PKC, as ROCK activates PKC (144-148). In parotid cells, 
activation of protein kinase A (PKA), a serine/threonine kinase, by adenylyl cyclase 
and cyclic AMP (cAMP) resulted in activation of PKCδ and released amylase (149). 
This indicated that MARCKS could potentially be phosphorylated and that the cAMP 
dependent/PKA pathway could indirectly regulate MARCKS function.  
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 Other than PKC activation, MARCKS also be phosphorylated by Protein 
Kinase G (PKG) through activation of cyclic GMP (cGMP) (150) in NIH-3T3 
fibroblasts. However, total reduction of MARCKS has also been observed in these 
cells, perhaps indicating that the PKG pathway is involved in its degradation (151). 
Additionally, in mouse, the p42 mitogen activated protein kinase (MAPK) has been 
shown to phosphorylate MARCKS on Ser113, a residue is present outside of the 
PSD (152).  
MARCKS phosphorylation also leads to its localization from the plasma 
membrane to cytosol (122, 128, 136, 153) or lysosome (154). Cytosolic 
phosphorylated MARCKS is dephosphorylated by protein phosphatase 1 (PP1), 
protein phosphatase 2A (PP2A) or calcineurin (calcium-bound protein) (155-159). 
Upon de-phosphorylation, MARCKS has been shown to bind to calmodulin, get 
cross-linked by filamentous actin (F-actin), or re-associate with cellular membranes, 
hence, validating MARCKS proposed role in cell migration.  
MARCKS role in reorganization of the actin cytoskeleton: 
 Many studies have determined that MARCKS is capable of binding to actin 
but the underlying mechanism is unclear. A general accepted hypothesis of 
MARCKS is that the PSD has two actin-binding motifs on the N-terminus and C-
terminus that are responsible for F-actin cross-linking. In addition, phosphorylation of 
MARCKS leads to conformational change within the PSD, which blocks one of the 
two acting binding domains. However, dephosphorylation of MARCKS also results in 




MARCKS has the ability to cross-link F-actin is promoted by both 
myristoylation and cleavage of MARCKS (163), as well as MARCKS phosphorylation 
at Ser25 (164). Furthermore, the PSD of MARCKS is able to bundle F-actin filaments 
and does so by binding to negatively charged residues of F-actin filaments, thus 
eliminating the electrostatic repulsion between F-actin filaments (165). Additionally, 
the MARCKS PSD is able to polymerize globular actin (G-actin) to F-actin. This 
mechanism is dependent upon the pentalysine sequence on the N-terminus of the 
PSD. Upon being phosphorylated by PKC or calmodulin binding, the ability of 
MARCKS to polymerize G-actin is inhibited (166). 
 A generally accepted hypothesis of MARCKS is that it helps in the movement 
of F-actin around the cell and helps other cytoskeletal proteins interact with F-actin 
as well. It has been established that myoblast alpha-5 integrin mediated focal 
adhesion needs functional MARCKS (140), and that MARCKS and F-actin are 
colocalized in blebs, lamellae of fibroblasts and membrane ruffles (167). Additional 
studies have shown colocalization of MARCKS with cytoskeletal proteins such as α3-
integrins and tetraspanins, proteins that form membrane complexes with integrins 
and participate in integrin-mediated cellular migration (168, 169).  
 Furthermore, an additional mechanistic hypothesis of MARCKS regulation of 
actin cytoskeleton has been demonstrated by sequestration of PIP2. It has been 
demonstrated that the continuous presence of PIP2 in the plasma membrane 
regulates actin dynamics. Wiskott-Aldrich syndrome protein (WASP) and ERM 
(ezrin, radixin, and moesin) proteins are actin-binding proteins that are activated by 
PIP2. Increased concentrations and decreased concentrations of PIP2 are the 
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signals for anchoring and releasing of the actin cytoskeleton from membranes (166, 
170, 171). Additionally, the MARCKS PSD binds to the plasma membrane 
phospholipids phoshatidylserine and PIP2 through electrostatic interactions (129, 
134, 172, 173). The unphosphorylated PSD of MARCKS binds to PIP2 and inhibits 
PLC mediated hydrolysis of PIP2 (174). On the plasma membrane, MARCKS 
clusters PIP2 molecules and PKC and Calmodulin mediated (CaM) displacement of 
MARCKS from the plasma membrane releases the sequestrations of PIP2, resulting 
in the hydrolysis of PIP2 by PLC (166, 174, 175). Taken together, these results 
demonstrate that sequestration of PIP2 is one of the mechanisms whereby MARCKS 
regulates actin dynamics.  
MARCKS participates in cell migration: 
 MARCKS role in cell migration should not be a surprise given that it regulates 
the actin cytoskeleton. MARCKS is required in the migration of fibroblasts (167), 
myoblasts (156), human embryonic kidney cells (176), human hepatic stellate cells 
(177) and vascular smooth muscle cells (178). The first step during cell migration is 
the cells ability to adhere to the extracellular matrix; and the role in MARCKS in 
regulation of cell adhesion and migration has been established (121, 140, 167, 169, 
179). Mutated MARCKS, where the myristoyl moiety is replaced by a palmitoyl 
moiety, interferes with the “MARCKS myristoyl-electrostatic switch mechanism”. This 
results in retraction of fibroblasts spreading on a fibronectin substrate. The 
palmitoylated MARCKS construct also interfered with early stages of cell spreading; 
this observation was confirmed by a round morphology with multiple membrane 
blebs. Additionally, fibroblasts expressing palmitoylated MARCKS exhibited 
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decreased numbers of membrane ruffles and lamellae at the leading edge of the 
cell. Thus, results from this study suggested that the defect was due to the inability 
of the cell to adhere to a fibronectin substrate (167).  
A role for MARCKS in cell migration has been elucidated in myoblast cells. 
Myoblasts express either wild type or non-myristoylated MARCKS and were capable 
of spreading on fibronectin, but myoblasts expressing MARCKS PSD null mutants 
were unable to spread on fibronectin. This observation suggested that the 
combination of phosphorylation and bi-lateral translocation of MARCKS was 
required for cell migration. 
An additional mechanism of MARCKS dependent cell migration occurs 
through stimulation of platelet derived growth factor (PDGF-BB). After stimulation 
with PDGF-BB, MARCKS shown to translocates from membrane to cytosol in Swiss 
3T3 fibroblasts (180). Further, upon PDGF-BB stimulation in hepatic stellate cells 
PKCε phosphorylated MARCKS. Additionally, MARCKS has been shown to 
associate with the PDGF-BB receptor but not focal adhesion kinase either in non-
stimulated and stimulated hepatic stellate cells. However, the non-stimulated hepatic 
stellate cells showed greater association of MARCKS with PDGF-BB receptor. 
Overexpression of MARCKS in hepatic stellate cells resulted in decreased PDGF-
BB mediated chemotaxis, whereas silencing of MARCKS using siRNA increased 
PDGF-BB mediated chemotaxis (160). These data support the concept that bi-lateral 
translocation of MARCKS is needed for the regulation of cell migration. Additionally, 
data also suggests that in migratory cells MARCKS is involved in stabilizing the actin 
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cytoskeletal structure.  However, MARCKS needs to be phosphorylated within PSD 
in order to promote cell migration and reorganize the actin cytoskeleton.  
 Contrary to the above mentioned observations, overexpression of MARCKS 
in cholangiocarcinoma cells (181) increased metastasis and decreased the host 
survival. Endogenous MARCKS overexpression and siRNA against MARCKS 
increased cell attachment and reduced cell attachment, respectively. Furthermore, in 
an experiment where cholangiocarcinoma cells were transfected with siRNA control 
and siRNA against MARCKS followed by treated of PKC inhibitor and TPA 
(translational inducer). The results showed inhibition of cell migration compared to 
pretreatment with TPA alone. This experiment suggested that MARCKS is need for 
migration and metastasis of cholangiocarcinoma cells in a PKC phosphorylation 
dependent manner (182).  
 As CELF1 is well-known for its post-transcriptional role in various cancer 
cells, we are particularly interested in how CELF1 controls mRNA translation in oral 
cancer cells. First, we have adapted a pSILAC technique to understand the 
proteome-wide translational effect of CELF1. From our preliminary data, we have 
identified a novel target, MARCKS. Second, MARCKS involvement in cell migration 
lead us to the following hypothesis that overexpression of CELF1 controls cell 
motility in oral cancer cells through controlling the expression of MARCKS. To 
support our hypothesis, we have designed the following specific aims: 1) we will 
determine whether CELF1 regulates MARCKS translation in oral cancer cells and 2) 








































Cell cultures were maintained in humidified atmosphere with 5% CO2 at 37°C. 
The human oral cancer cell lines (HOK, UM74B, UM11A, UM11B, UM22A and 
UM22B) were maintained in Dulbecco’s modified Eagle medium (DMEM-Hyclone, 
Logan, UT) containing 10% fetal bovine serum (FBS) (Seradigm, Randor, PA) with 
100 U/ml penicillin and 100 µg/ml streptomycin (Hyclone, Logan, UT). Normal 
human oral keratinocyte cells (HOKs) (ScienCell, Carlsbad, CA) and non-malignant 
immortalized oral keratinocytes (OHKC/OKF6-TERT) were grown in keratinocyte 
serum-free medium supplemented with Bovine pituitary extract (BPE) and epidermal 
growth factor (EGF) (Gibco, Grand Island, NY).  
Preparation of shRNA lentivirus particles 
 Cells were plated and after 6-8 hrs of incubation, shcontrol and shRNA 
directed against CELF1 were transduced at 50 MOI (multiplicity of infection) (viral 
particles were prepared by Dr. Reniqua House) in DMEM medium with 1 µg/mL 
polybrene final concentration. After 16-18hrs of incubation, the medium was 
replaced with fresh media. Cell were further incubated for 96-120 hrs and collected 
for further analysis.  
Pulsed stable isotope labeling of amino acids in cell culture (pSILAC) 
 Twenty-four hours after transfection of UM74B cells with siRNA, the medium 
was changed to DMEM containing L-Lysine-2HCl and L-Arginine-HCl (light amino 
acids) for 48 hours (Pierce-DMEM SILAC quantitation kit). After 48 hours in the 
presence of light amino acids the medium on siControl treated cells was changed to 
DMEM containing L-Lysine-2HCl, 4,4,5,5-D4 (medium amino acids) and the medium 
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on siCELF1 treated cells was changed to DMEM containing L-Lysine-2HCl, 13C6, 
15N2 (heavy amino acids) for 24 hours.  Cells were lysed in 9 M Urea and 20 mM 
HEPES, pH 8.0 and rocked for 4hours at 4ºC. Lysates were combined at a 1:1 ratio 
(200µg of each sample) and send for mass spectrometry analysis (Unpublished 
observation from House et al) (183). 
LC MS/MS Analysis—Orbitrap Elite w/ETD 
Peptides were separated with a linear gradient of 5–50% buffer B (95% ACN 
and 0.2% formic acid) at a flow rate of 200nL/min on a C18-reversed phase column 
(75 mm ID _15 cm) packed in-house with Waters YMC-ODS C18-AQ 5 mm resin in 
buffer A (0.2% formic acid/95% water/5% Acetonitrile). A Dionex U3000 nano-LC 
chromatography system (Thermo Scientific) was on-line coupled to the Orbitrap Elite 
instrument (Thermo Scientific) via a Nanospray Flex Ion Source (Thermo Scientific). 
MS data were acquired in a data-dependent strategy selecting the fragmentation 
events based on the precursor abundance in the survey scan (400–1700 Th). The 
resolution of the survey scan was 60,000 at m/z 400 Th with a target value of 1e6 
ions and 1 microscan. Low resolution CID MS/MS spectra were acquired with a 
target value of 5000 ions in normal CID scan mode. MS/MS acquisition in the linear 
ion trap was partially carried out in parallel to the survey scan in the Orbitrap 
analyzer by using the preview mode (first 192 ms of the MS transient). The 
maximum injection time for MS/MS was 100 ms. Dynamic exclusion was 120 s and 
early expiration was enabled. The isolation window for MS/MS fragmentation was 
set to 2 Th. 
Database Search and Quantitation 
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The three triple pSILAC experiments were searched and quantitated together 
as 3 experiments using Maxquant v 1.4.1.2. The Human IPI v3.72 database was 
used. Static modification of carbomidomethyl on cysteines and variable 
modifications of methionine oxidation were included. All protein identifications were 
determined with a 1% FDR as determined by Maxquant.  
Polysome gradient analysis 
Cells were lysed in hypotonic lysis buffer (100 nM Tris-Cl pH 7.4, 5 mM 
MgCl2, 1% Triton X-100, 0.5% deoxycholate, 2 mM DTT, prepared in DEPC-treated 
water) and equivalent amount of protein were overlayed onto a sucrose gradient (10- 
50% (w/v) (increment of 10%), 100 nM KCl, 5 mM MgCl2, 2 mM DTT, 20 mM 
HEPES-KOH pH 7.4, prepared in DEPC-treated water). Gradients were centrifuged 
at 35,000 rpm for 3 hours at 4°C in an ultracentrifuge using Ti-40 rotor. Twenty to 
twenty-five 600uL fractions were collected and RNA was extracted using TRIzol® 
reagent (Ambion, Grand Island, NY) according to the manufacturer’s protocol. 
Extracted RNA was run on a 0.8% agarose gel (10 mL of 10x MOPS, 62 mL of 
DEPC treated water and add 18 mL of 37% formaldehyde once the agarose is 
dissolved in the solution) (Sigma, St. Louis, MO). Afterwards, based on separation of 
tRNA, 40S, 60S, 80S, and multiple polysome (18S and 28S ribosome subunits), 
fractions were combined and run on a 1% agrose gel. Complementary DNA was 
synthesized for combined fractions, using Tetro cDNA Synthesis kit oligo dT primers 
(BIOline, Taunton, MA).  Semi quantitative RT-PCR was run for the top 18 genes 
associated with CELF1 (Table 1). Polysome fractionation analysis was standardized 
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with help of Dr. Phil Howe’s laboratory in the Department of Biochemistry and 
Molecular Biology. 
Semi quantitative RT-PCR reaction of RNA isolated from polysome fractions 
Total RNA was isolated from cells using Trizol according to manufacturer’s 
protocol (Ambion, Grand Island, NY). Reverse transcription was performed using the 
Tetro cDNA Synthesis kit (BIOline, Taunton, MA). Quantitative PCR was performed 
using the Eppendorf vepo-protect instrument and cycle conditions were set as 
follow: 1st step: Initial 95° of denaturation for 10min, 2nd step: additional 5min of 
denaturation at 95°, 3rd step: annealing of primers at 64° for 30 seconds, 4th step: 
primer extension at 72° for 30sec and steps 2-4 repeats for 30 times). Briefly, 
reactions were prepared using 10 ul of total RNA from each pooled fraction, MY Taq 
mix (Bioline, Taunton, MA) and human-specific primers for MARCKS (IDT 
Technology, Coralville, IA) (Sense: 5ʹ′- CCC ACA GAT CCC ATC TCA AAT C-3ʹ′, 
anti-sense: 5ʹ′-GAG AAA CAA GGC AGA GGA AGA A -3ʹ′). All samples were run in 
triplicate and normalized to GAPDH (Sigma, St. Louis, MO) (Sense: 5ʹ′-GGT GGT 
CTC CTC TGA CTT CAA CA-3ʹ′, anti-sense: 5ʹ′-GTT GCT GTA GCC AAA TTC GTT 
GT-3ʹ′). Briefly, 1µL of cDNA, 4µL primer (1µM final concentration), 5µl DEPC treated 
water and 10µl of 2X MyTaq mix for 20ul final reaction.  
siRNA transfection (MARCKS) 
 Cells were plated at twenty percent confluency. After incubating for 6-8 hours, 
either siControl (20nM; GTTCAATTGTCTACGCTA) or on-TARGETplus SMARTpool 
siRNA-targeting MARCKS (20nM; GAG AAG GCG GUG AGG CUG A, GAA GGU 
AAA CGG CGA CGC U, CAU AGG AACU UUU CACU UA and AAA UUG AAG 
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UGG UGC AUA A) (Dharmacon RNAi Technologies) was transfected (17 hrs) using 
HiPerfect as the transfection reagent (Qiagen, Valencia, CA), following the 
manufacturer’s protocol.  
Western Blot analysis 
Cells were lysed on ice by vortexing 4–5 times in RIPA buffer [2 mM TRIS-
HCl, 30 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, complete protease 
inhibitor cocktail (Boston Scientific, Marlborough, MA), 1% NP-40, pH 7.6] at 5 min 
intervals, followed by centrifugation at 12,000 × g for 30 min at 4°C. Supernatants 
were mixed with an equal volume of 2X Laemmli’s buffer and heated for 5 min at 
95°C. Total protein concentration was estimated using a Bradford assay. Forty to 
fifty micrograms of total protein was resolved on 10% SDS-PAGE gels for 1 hour at 
110 volts and transferred onto a PVDF membrane (EMDmillipore, Billerica, MA) for 
45 minutes at 15 volts using a semidry transfer system. Membranes were pre-
incubated for 1 hr with 5% skim milk (block) prior to incubation with primary antibody 
against the target protein overnight at 4°C. After overnight incubation, the membrane 
was washed three times with tris-buffered saline containing 0.1% Tween 20 (TBST) 
and incubated with 1% skim milk containing 1:5,000 diluted HRP-conjugated 
secondary antibodies for 1 hr at room temperature. After additional washing with 
TBST, immune complexes were visualized using the ECL system (Pierce). Blots 
were re-probed with anti-β-actin antibody as described above. Western blot analyses 
were performed by using antibodies specific to CELF1 (1:1000) (EMDmillipore, 
Billerica, MA), MARCKS (Cell Signaling, Danvers, MA) (1:1000) and β-actin (Sigma, 
St. Louis, MO) (1:5000).  
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RNA extraction and Quantitative Real-time PCR (qRT-PCR)  
Total RNA was prepared from HNSCC cell lines using the RNeasy mini kit 
(Qiagen, Valencia, CA)). qRT-PCR for all mRNA targets were performed using an 
Applied Biosystems StepOne Plus system with the iScript cDNA synthesis kit 
(BioRad).  Briefly, one microgram of total RNA was used for cDNA synthesis. cDNA, 
was diluted 1:5 for qPCR. Quantative PCR reaction was as follows: 1µL of cDNA 
(from 1:5 diluted stock), 1µL of primer (5uM stock primers) and 5µL of 2X Syber 
green dye (Final concentraiton of 1X) (Qiagen, Valencia, CA). CELF1 primers 
sequecne as follow: sense: 5ʹ′-CCA GAC AAC CAG ATC TTG ATG CT-3ʹ′, anti-
sense: 5ʹ′-AGG TTT CAT CTG TAT AGG GTG ATG-3ʹ′. MARCKS and GAPDH 
sequences are identical to sequences that are mentioned in the semi quantitative 
RT-PCR reaction section. 
Ribonucleoprotein immunoprecipitation (RNP- IP)  
CELF1 antibody (EMDmillipore) (4 µg /1mg cell extract) was coated onto 50-
60 µL protein G agarose beads per 1 mg of whole cell extract in a total of 1mL NT2 
buffer  (50 mM Tris-Cl pH 7.4, 150 mM NaCl, and 0.5% NP-40). UM74B cell pellets 
were resuspened in polysome lysis buffer (100mM HEPES pH7, 1 M KCl, 50 mM 
MgCl2, 0.25 M EDTA, and 5% NP-40) and placed in -80°C overnight. Antibody-bead 
complexes were allowed to form overnight at 4°C on a rotating device. Next day, 
lysates were cleared by centrifugation at 14,000 rpm for 10 min. Antibody coated 
beads were washed 4-6 times with NT2 buffer. For each IP, the antibody coated 
beads were resuspended in 850 µL NET2 buffer (850 µL NT2, 10 µL 0.1 M DTT, 30 
µL 0.5 M EDTA, 2.5 µl RNase OUT, and 5 µL SuperaseIN) and 100 µL RNP lysate 
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was added, centrifuged briefly, and a 100µl aliquot was removed for input purpose. 
The RNP lysate-bead complexes were rotated overnight at 4°C. On day three, the IP 
material was centrifuged at 3000g for 3 min and the beads were washed with NT2 
buffer 4-6 times. To dissociate the RNP complex from the antibody coated beads, 
the beads were resuspended in 100µl of NET2 and 100µl of 2X proteinase K buffer 
(20 mM Tris-Cl pH 7.5, 20 mM EDTA, 100 mM NaCl, 2% SDS, stored at room 
temperature), after which 3µl of proteinase K (Sigma, St. Louis, MO) was added and 
the solution was incubated at 55°C for 30min with occasional mixing. Afterwards, the 
supernatant was transferred into new tubes. Finally, RNA was isolated using Trizol 
(Life Technologies, Carlsbad, CA). 
Overexpression of GFP-tagged MARCKS  
 The GFP-tagged MARCKS plasmid was purchased from OriGene (OriGene, 
Rockville, MD). UM74B cells (1x105) were seeded in a 24-well dish and transfected 
with 0.25 µg of MARCKS-GFP tag or GFP empty vector using 0.5-1uL of 
liptofactamine 2000 (Life Technologies, Carlsbad, CA).  
Wound healing assay (scratch assay) 
OHKC, OHKC CELF1 Flag tag (stable cell lines), UM74B MARCKS-GFP 
expressing cells were seeded in a 6-well plate. Wounds were created on cell 
monolayers using a 10µL pipette tip. At 0hr and 24hrs, images were captured using 
Nikon Eclipse TS100 with NIS-Element Br3.2 software (Melville, NY). Wound closure 
was quantified using ImageJ software.  
Transwell migration assay 
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 Fifty thousand cells of shRNA control plus GFP, depleted CELF1 plus GFP 
and depleted CELF1 with plus MARCKS-GFP were resuspended in 5 µL of serum- 
free medium containing 100 U/mL penicillin and 100 µg/mL streptomycin and plated 
into the upper well of a 24-well transwell (Corning). Transwells were placed into a 
24-well plate containing complete medium. Cells were allowed to migrate for 24 hrs. 
Cells were stained with Hoechst 33442 for 30 minutes and the transwell membranes 
were mounted on to slides. Migrated cells were counted in 4 random fields of view at 
10x magnification using a fluorescent microscope. Percent migrated cells were 
calculated by ImageJ software.  
Statistical Analysis 
All the experiments were conducted in triplicate analysis with mean and 
standard deviation was calculated. A student t-test was performed for most of the 
studies, with two-tailed distribution and a two-sample unequal variance. A p-value of 

































































 RNA-binding proteins are known to be involved in the regulation of gene 
expression at post-transcriptional levels, but they do not act alone, instead they 
function as a ribonucleoprotein complex with RBPs and mRNAs. CELF1 
coordinately control the expression of multiple target genes at the posttranscriptional 
level. CELF1 was formerly demonstrated as an multifunctional protein that regulates 
many post-transcriptional processes including alternative splicing, mRNA 
deadenylation, decay and some extend translation (184). Several reports indicated 
that CELF1 play a key role in mRNA turnover, but its role in global mRNA translation 
remains largely unidentified.  
Previous work from our laboratory reported that overexpression of CELF1 in 
head and neck tumor tissues compared to normal adjacent tissue samples (185), 
suggesting that overexpressed CELF1 play a role in oral cancer progression.  In 
addition, unpublished observations from our laboratory indicate that CELF1 is 
capable of controlling the splicing and turnover of approximately 1500 mRNAs and 
translation of over 1350 mRNAs. Since there are no studies showing CELF1’s role in 
global mRNA translation in cancer model, we were particularly interested in 
understanding CELF1’s role in mRNA translation in OSCC cells. To identify the 
CELF1-mediated global mRNA translation control, we have adapted a novel 
proteomics approach called the pulsed stable isotope labeling of amino acids in cell 
culture (pSILAC) using oral cancer cells (Schematic 1). pSILAC is a technique based 
on mass spectrometry that detects difference in protein abundance among different 
conditioned samples using non-radioactive isotopic labeling (186). Using pSILAC we 
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have identified approximately 1350 genes that were controlled by CELF1.  Further 
analysis of the pSILAC data revealed a novel gene; myristoylated alanine-rich C-
kinase substrate (MARCKS) which was significantly affected by the absence of 
CELF1.Hence, we wish to determine how CELF1 controls MARCKS at the post-






















Specific Aim #1: To determine whether CELF1 controls MARCKS translation in 
oral cancer cells. 
Task 1: Determine the mRNA and protein expressions of CELF1 and MARCKS in  
multiple OSCC cells (UM74B, UM11A, UM11B, UM22A & UM22B) by qRT-
PCR and Western blotting analysis.  
Task 2: Determine if CELF1 expression proportionately correlates with MARCKS 
expression through Western blot analysis in UM74B and UM22B cells.  
Task 3: Verification of the pSILAC data using polysome gradient analysis and semi- 
quantitative PCR followed by agarose gel analysis.  
Task 4:  Establish if CELF1 specifically controls MARCKS expression at the mRNA  
translational level, by measuring MARCKS mRNA in CELF1 depleted cells. 
Task 5: Determine the association between CELF1 and MARCKS mRNA through  












First, unpublished results from our laboratory revealed that CELF1 controls 
the translation of several target mRNAs in oral cancer cells. Second, we have used 
the following criteria to select a subset of proteins from our pSILAC experiment for 
further evaluation; 1) top altered proteins identified based on statistical analysis, 2) 
mRNAs that contain GRE’s at their 5ʹ′ or 3ʹ′ UTRs, and 3) top proteins that are 
involved in cancer cell biological processes. Figure 1 demonstrates that upon 
depletion of CELF1 in UM74B cells, only 56 proteins were up-regulated, but 1294 
proteins were down-regulated in comparison to control cells, suggesting that CELF1 
is a global translation regulator in OSCC cells. Third, enrichment analysis of pSILAC 
data indicate that diverse sets of genes are controlled by CELF1, and their coding 
proteins are involved in biological functions such as mRNA surveillance, RNA 
binding and translation (Figure 2). Based on the pSILAC proteome-wide analysis, we 
have identified top18 proteins coding mRNAs contains canonical GRE’s at their 
UTRs (Table 1). Using Kyoto encyclopedia of genes and genomes (KEGG) pathway 
for biological function, UCSC genome browser database for GRE sequence search, 
and polysome fractionation gradient analysis for mRNA translation, we have 
identified MARCKS as a target of CELF1 in oral cancer cells (Table 1 and Figure 8). 
Thus, the specific aim-1 of this thesis is planned to test whether CELF1 regulates 
MARCKS mRNA translation in oral cancer cells. Therefore, to determine the 
expression level of CELF1 and MARCKS in oral cancer cells, first, we have tested 
the protein levels of MARCKS and CELF1 in oral cancer cells in comparison with 
primary normal human oral keratinocytes (HOK). Our Western blot analysis revealed 
that the protein expression-fold change of MARCKS and CELF1 are greater than 2 
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fold in UM74B, UM11A, UM11B, UM22A, and UM22B oral cancer cells compare to 
HOK cells (Figure 3). Interestingly, most of the oral cancer cells did not exhibit 
significant differences in CELF1 and MARCKS mRNA expression compared to HOK 
cells (Figure 4), exceptions are UM11B and UM22A cell lines. Altogether the results 
obtained from Figures 3 and 4 indicated that MARCKS protein expression was 
relatively higher compared to its mRNA levels in OSCC cells. Which allows us to 
conclude that MARCKS may be regulated at the post-transcriptional level, in 
particular at the mRNA translation step in oral cancer cells.  
Next, we sought out to validate our pSILAC data using the Western blotting 
technique. First, CELF1 was depleted in UM74B and UM22B cell lines using shRNA 
directed against CELF1 with appropriate shRNA control lentiviral particles. Ninety-six 
hours of post-viral infection, cells were collected and proteins were extracted for 
Western blot analyses. The data obtained from this study indicated that both UM74B 
and UM22B cells exhibited reduced MARCKS expression in CELF1 depleted cells 
compared to control shRNA treated cells (Figure 5). We observed 80% depletion of 
CELF1 reduced MARCKS expression by 48% in UM74B cells (Figure 5) and a 60% 
reduction in CELF1 in UM22B cells resulted in a 58% decrease in MARCKS 
expression (Figure 6). Thus, the data obtained from these studies demonstrated that 
reduction of CELF1 reduced the expression of MARCKS at the protein level in oral 
cancer cells.  
To further confirm the data obtained from pSILAC and Western blot analysis 
of MARCKS, we have utilized polysome fraction gradient analysis to understand 
CELF1’s role in mRNA translation of MARCKS. First, we treated the UM74B cells 
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with either control shRNA or shRNA against CELF1 to knockdown CELF1. Next, we 
have extracted the protein lysates for polysome gradient analysis. The fractions 
obtained from polysome gradient were subjected to RNA extraction to test the 
relative expression levels of different RNA species. As expected, we have observed 
a separation of tRNA (free flowing RNA), 40S (ribosomal subunit), 60S (ribosomal 
subunit), 80S/monosome subunits (complex of 40S and 60S ribosomal subunits) 
and multiple polysomes in shRNA control and shRNA CELF1-treated cell polysome 
fractions (Figure 7, top panel). The bottom panel in Figure 7 illustrates the 
schematics of the polysome gradient profiles. Next, we used semi-quantitative PCR 
analysis of combined polysome fractions to estimate the mRNAs undergoing active 
translation in oral cancer cells. The RNA extracted from polysome fractions were 
subjected to estimate MARCKS mRNA by using gene specific primers.  The cDNA 
was prepared from total RNA and subjected to semi-quantitative PCR for measuring 
MARCKS mRNA level. The PCR products were separated by using agarose gel and 
the relative expression of MARCKS mRNA was measured. The results obtained 
from this experiment indicated that there is reduction of MARCKS mRNA in active 
translation fractions of shRNA CELF1 treated samples in comparison to active 
translation fractions in cells treated with shRNA control (Figure 8). Thus, the data 
obtained from this section of the study indicated that CELF1 directly controls the 
expression of MARCKS at the mRNA translation level.  
Next, to test whether CELF1 is controlling MARCKS translation through its 
mRNA levels, we measured the relative expression level of MARCKS mRNA in 
CELF1 depleted UM74B and UM22B cell lines. Both cell lines were treated with 
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either shRNA control or shRNA against CELF1 viral particles and 96 hours post-
transduction the lysates were prepared for RNA extraction and analyzed by qRT-
PCR. The results indicated that reduction of CELF1 in UM74B and UM22B cells did 
not significantly alter MARCKS mRNA levels compared to shRNA control cells 
(Figure 9 and 10). This observation clearly demonstrated that CELF1 controls 
MARCKS protein expression at the mRNA translation level but not at the expression 
of mRNA. Finally, to determine if CELF1 directly bound to MARCKS mRNA and 
control its translation, we performed RNP-IP assays using an anti-CELF1 antibody 
and an IgG control. We have observed a 3.8 fold enrichment of MARCKS mRNA in 
CELF1 immunolysates (Figure 11) compared with IgG control beads. These data 
suggest that CELF1 directly binds MARCKS mRNA and promotes its translation in 
oral cancer cells.  
In specific aim-1, we have now established that overexpression of CELF1 
appears to regulates MARCKS expression in various oral cancer cell lines. 
Specifically, depletion of CELF1 in oral cancer cells reduced MARCKS protein 
expression, but did not changing the level of mRNA. Furthermore, RNP-IP assays 
revealed that CELF1 directly associated with MARCKS mRNA. In summary, taking 
all of these data in specific aim-1, we have now demonstrated that CELF1 controls 















Table 1: Top genes showing significant differences in expression patterns by 
pSILAC analysis. These genes were selected based on their GRE motif in their 3' 
UTR.  
Proteins)) GRE)Clusters)
Up)Regulated) Fold)Change) Cluster) 3!)UTR)GRE)
EPS8% 2.27% Cluster%4% TTGTTTGTTTGTA%
COL5A3% 2.86% 9%
PTPN11% 1.59% 9%
SPEN% 1.96% Cluster%3% TTTTGTTTGTTTG%
Down)Regulated))
SNRPD3% 94.53% 9% 9%
SUMF2% 94.42% 9% 9%
LUZP1% 94.36% 9% 9%
SFRS2% 93.88% 9% 9%
AKR1D1% 93.53% Cluster%5% TGGTGTTTGTTTC%
NCAPG% 93.40% Cluster%5% TTCTGTTTGTTGG%
ATF7IP% 92.92% Cluster%5% GGGTGTTTGTGTG%
ERCC5% 92.89% Cluster%5% TTGTGTTTGATGG%
ADNP% 92.73% Cluster%5% TTTTGTTTGTTTT%
EPS15% 92.65% Cluster%5% TTATGTTTGTTGT%
COPZ1% 92.65% Cluster%5% TTCTGTTTGTGGT%
STK10% 92.65% Cluster%5% TTGTGTTTGTTGT%
MARCKS% 92.64% Cluster%4% GTTTGTTTGTTGG%














Schematic 1: Illustration of pulsed stable isotope labeling of amino acids in 











Figure 1: Histogram of log2 fold change versus expression of proteins altered in 
the absence of CELF1 in UM74B oral cancer cells. In absence of CELF1, 










Figure 2: Enrichment analysis of CELF1 regulated proteins using cluego and 
cluepedia (cytoscape). The enrichment analysis of pSILAC has identified CELF1’s 
role in various cell processes, including mRNA surveillance, cytoskeleton 
reorganization, mRNA 3’ end processing and translation. The three triple pSILAC 




Figure 3: Western blot analysis of MARCKS and CELF1 in oral cancer cell 
lines in comparison to normal human oral keratinocytes. Beta-actin serves 
as a loading control. Double band of CELF1 reflects possible post-




















Figure 4: Relative quantity of mRNAs measured with qRT-PCR in oral cancer cells. 
CELF1 mRNA expression was significantly altered in UM11B and UM22A; 
additionally, MARCKS mRNA expression was also significantly altered in UM74B in 
comparison to HOK cells.  N=3, MARCKS: *p<0.027 (UM74B); CELF1; CELF1: 





























Figure 5: Reduction of CELF1 in UM74B cells influences MARKCS protein 
expression. Western blot analysis of CELF1 and MARCKS in oral cancer 
cells, and beta-actin serves as a loading control. Bottom graph depicts 
quantitative values of representative Western blots expression levels of 


























Figure 6: Reduction of CELF1 in UM22B cells influences MARKCS protein 
expression. Western blot analysis of CELF1 and MARCKS in oral cancer cells, 
and beta-actin serves as a loading control. Bottom graph depicts quantitative 
values of representative Western blots expression levels of CELF1 and 







Figure 7, top: Polysome gradient fractionation analysis of CELF1 depleted cells. The 
standardization of polysome fractionation analysis have shown separation of free flowing 
RNA, 40S ribosome subunits, 60S ribosomes subunits, 80S subunits (non-active translation) 
and polysome (active translation). N=2. 















Figure 8: Semi-quantitative PCR analysis of CELF1 depleted UM74B polysome 
fractionations. The control samples shows lesser amount of MARCKS mRNA present 
in the non-active translation (free flowing tRNA, 40S, 60S and 80S fractions) in 
comparison to active translation (polyosme fractions). In the depleted samples, more 
MARCKS mRNA present in the non-active translation fractions compared to active 




































Figure 9: Depletion of CELF1 did not alter MARCKS mRNA in UM74B cells.  
qRT-PCR analysis of CELF1 and MARCKS in the absence of CELF1 oral 
cancer cells.  Depletion of CELF1 does not alter MARCKS mRNA in UM74B. 













Figure 10: Knockdown of CELF1 did not alter the expression of MARCKS mRNA 
in UM22B cells. qRT-PCR analysis of CELF1 and MARCKS in the absence of 
CELF1 oral cancer cells.  Depletion of CELF1 does not alter MARCKS mRNA in 











Figure 11: CELF1 associated with MARCKS mRNA identified by RNA-IP. The 
UM74B cell lysate was immunoprecipitated with IgG or anti-CELF1 antibody. 
The RNAs isolated from the total lysate and the immunoprecipitates (IP) were 
then anlauyzed by qRT-PCR. The qRT-PCR showed 3.8 fold enrichment in the 




 Gene expression is a tightly regulated and adaptive process that 
encompasses co- and post–transcriptional modifications and ultimately determines 
the fate of the mRNA. The mRNA translation is a key post-transcriptional regulatory 
process in eukaryotes, and deciphering CELF1-mediated protein translation 
provides an opportunity to dissect this pathway in cancer cells. Interestingly, at 
different stages of development, CELF1 can activate the translation of various 
mRNAs (102). For example, in Drosophila CELF1 protein called Bru forms a 
complex with protein CUP and the 5ʹ′ cap binding initiation factor, eIF4E, and initiates 
circularization of mRNA and inhibit its translation (104). In addition, interaction of 
CELF1 with hnRNP H at the two ends of the SHMT (folate-dependent enzyme) 
transcripts also aid in circularization and facilitate translation from an internal 
ribosome entry site (IRES) by increasing ribosome recycling (112, 113). Altogether, 
these studies support CELF1 as a regulator of mRNA translation in different cell 
systems. 
From our pSILAC analysis we have identified MARCKS as a target of CELF1 
protein at the mRNA translational level. Notably, CELF1 and MARCKS are 
overexpressed in oral cancer cells compared to normal oral keratinocytes (Figure 3), 
which demonstrate the importance in the coexistence of these proteins in oral 
cancer cells. Surprisingly, we did not see significant changes in the level of mRNA 
(Figure 4) encoding MARCKS in the absence of CELF1, indicate that MARCKS 
protein expression levels are post-transcriptionally regulated at the translation level. 
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Thus, CELF1’s role in mRNA translation has been established, and the target 
MARCKS has been identified in oral cancer cells.  
 Specific deletion of CELF1 followed by measurement of MARCKS protein 
expression in UM74B and UM22B cell lines using Western blot analysis clearly 
established a relationship between CELF1 and MARCKS (Figure 5 and 6). In both of 
the cell lines, we have observed that deletion of CELF1 protein leads to significant 
reduction of MARCKS protein levels. In contrast to this observation, recent reports 
have indicated that CELF1 along with another RBP, HuR (Hu Antigen-R) are shown 
to regulate translation of occluin mRNA by binding at its 3ʹ′ UTR (187). 
Overexpression of CELF1 decreased the HuR binding to occluin mRNA and 
repressed its translation, whereas HuR overexpression inhibited CELF1 association 
with occluin mRNA and promoted its translation (187). These data suggests that 
RBPs copete with each other for binding and involved in the regulation of mRNA 
translation depending on the transcript. We assume that CELF1 possibly associates 
with the 3ʹ′ and/or 5ʹ′ UTR of MARCKS and controls its translation. Utilizing the UCSC 
genome browser database query, we were able to observe that the 3ʹ′ UTR of 
MARCKS contains the canonical GRE sequence UGUUUGUUUGU and the 5ʹ′ UTR 
contain several GU and U stretches, where CELF1 thought to bind and regulate its 
protein expression levels. Moreover, our RNP-IP analysis clearly demonstrated that 
CELF1 is strongly associated with MARCKS mRNA. As CELF1 was shown to bind 
to mRNAs containing UGU triplets (188), we have observed several triplets of UGU 
at the MARCKS 3ʹ′ UTR. In addition, CELF1 enhanced the translation of cyclin A2 
through binding consensus sequences in its 3ʹ′ UTR, indicating that CELF1 also 
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targets the 3ʹ′ UTR of mRNAs to regulate its translation (102). Collectively, other 
reports mentioned above and our data suggests that CELF1 interact with MARCKS 
and controls its translation in oral cancer cells. Currently, to delineate the exact 
mechanism of CELF1 binding with MARCKS mRNA, we are investigating the 
MARCKS 3ʹ′ UTR association with CELF1 using the 3ʹ′ UTR reporter assays.  
 In order to strengthen the pSILAC data, we have adapted polysome 
fractionation analysis. The separation of tRNA (free flowing RNA), 40S (ribosomal 
subunit), 60S (ribosomal subunit), 80S/monosome subunits (complex of 40S and 
60S ribosomal subunits) and multiple polysomes in shRNA control and shRNA 
CELF1 depleted cells were achieved (Figure 7, top panel). The separation of tRNA, 
40S and 60S ribosome, 80S ribosome and multiple polysome fractions are important 
to determine the active vs. non-active translation of particular mRNA, with inactive 
translated mRNAs predominately found in the free flowing RNA, 40S, 60S and 80S 
and actively translated mRNAs found in multiple polysome fractions. The fractions 
were subjected to semi-quantitative PCR analysis and showed significant reduction 
of MARCKS mRNA in polysome fractions, of cells treated with shCELF1 compared 
to cells treated with shcontrol (Figure 8). The reduction of MARCKS mRNA in 
polysome fractions demonstrated that it was not undergoing active translation in the 
absence of CELF1. It has been shown that a model for the IRES-mediated 
translation of SHMT1 (serine hydroxymethyltransferase 1), whereby the 
circularization of the mRNA typically provided by the eukaryotic initiation factor (eIF) 
4G/PABP/poly(A) tail interaction is achieved through the hnRNP H2/CELF1-
mediated interaction of the 5ʹ′ and 3ʹ′ UTR of the SHMT1 transcripts (112). Our 
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observations indicate that CELF1 might interact with either the 3ʹ′ or 5ʹ′ UTR of 
MARCKS and possibly forms a circularization with mRNA and regulate its 
translation.  
 As CELF1- is controlling the expression of MARCKS, the changes in 
MARCKS mRNA turnover needs to be addressed. Interestingly, in the absence of 
CELF1 both UM74B and UM22B cells did not exhibit significant changes in the 
expression of MARCKS mRNA (Figure 10 and 11), instead it exhibits reduced 
MARCKS protein level, demonstrated that the CELF1 solely act on the mRNA 
translational level and promoted the expression of MARCKS. Under certain 
circumstances, the absence of one RBP might recruit additional RBPs to associate 
with target mRNAs. For example, a recent report indicated that CELF1 could bind to 
the 3ʹ′ UTR of Myc mRNA repressing its translation without affecting total Myc mRNA 
levels. Interestingly, HuR interacted with the same Myc 3ʹ′ UTR element, and 
increasing the level of HuR, decreased CELF1 binding to Myc mRNA (189).  It has 
been shown that the 3ʹ′ UTR of MARCKS contains canonical AU-rich sequences 
(190), which are known to interact with HuR, but this observation needs further 
investigation. Thus, RBPs can interplay between each other to bind with mRNAs and 











































 Cell migration is an important for physiological processes that depend on 
regulated movement of cells, including immune responses, embryonic development 
and tissue maintenance and repair. In addition, alteration in cell motility plays a role 
in driving disease states such as; vascular disease, chronic inflammation and tumor 
metastasis (191). Tremendous efforts have been made to understand these aberrant 
changes in diseases. These efforts uncovered the current concept of cell migration, 
which is a cycle of several tightly regulated steps (191, 192). For example, 
directional movement of the cell is initiated by polarization of cells to migratory cues 
(191). Cell polarization, allows for the segregation of machinery that regulates the 
multiple states of migratory cycle (191). A migratory cycle consists of (1) the cell 
extending an actin cytoskeletal-rich protrusion that occurs in the leading edge of the 
cell toward the migratory cue, (2) the leading edge attaches to the extracellular 
matrix (ECM) through-integrin mediated adhesion complexes, (3) the actin-myosin 
cytoskeleton generates force to move the bulk of the cell forward and lastly, the 
adhesive contacts at the rear of the cell are disassembled to complete the cycle 
(191). Thus, any irregularity in the cycle mentioned above can lead to altered cell 
motility and potentially promote diseases. 
 Interestingly, CELF1s role in cell migration has not been addressed so far. 
However, based on our pSILAC proteomic analysis and gene ontology, we were 
able to identify CELF1-targetted genes that are involved in cell migration and 
motility. Therefore, for specific aim-2 of this study, we will examine how CELF1 




Specific Aim 2: Determine the biological role of MARCKS in oral cancer cells. 
Task 1:  Determine if CELF1 modulates cell migration in UM74B cells by using a  
wound scratch healing assay. 
Task 2: Confirm whether overexpression of CELF1 promotes the expression of  
MARCKS in non-malignant human oral keratinocytes and enhances cell 
motility. 
Task 3: Understand if MARCKS directly controls cell motility in UM74B cells using a  
cell migration assay. 
Task 4: Establish if ectopic expression of MARCKS in CELF1 depleted UM74B  
























Although pSILAC and gene ontology analysis suggest that CELF1 could play 
a role in cell-cell communication and regulate extra cellular matrix proteins in oral 
cancer cells (Figure 2), its cell migratory functions were never tested in a cancer cell 
model. To address whether depletion of CELF1 in UM74B cells modulate cell 
motility, we employed two separate methods to quantify cell migration: a wound 
healing assay and a transwell migration assay.  First, to measure the cell migration 
in UM74B cells, we created a scratch 72 hours post-transduction shRNA control and 
shRNA against CELF1, a wound was created as described in materials and 
methods. Next, the percent migration was calculated by measuring wound closure at 
0 and 24-hours post wounding for control and CELF1 depleted cells. Compared to 
control shRNA treated cells, we have observed a 56% reduction in wound closure in 
the CELF1 knockdown cells (Figure 12), suggesting that CELF1 promotes cell 
migration in oral cancer cells.  
To further confirm CELF1’s role as a cell migratory protein, we tested its 
function by overexpressing CELF1 in non-malignant oral keratinocytes (OHKC), 
which express low levels of CELF1 and measured cell migration. By using wound 
scratch assay, we have observed OHKC CELF1 overexpressing cells to exhibits 
49% enhancement in cell migration compared to control OHKC (Figure 13).  This 
observation indicated that CELF1 enhanced cell migration, possibly through its 
associated gene network.  
Next, to test whether overexpression of CELF1 in OHKC cells promotes 
MARCKS protein expression, we have used Western blot analysis. CELF1 
overexpressing OHKC cells exhibited a 2.7 fold increase in MARCKS protein 
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compared to control vector-expressing cells  (Figure 14, left panel). This observation 
clearly indicated that overexpression of CELF1 promoted MARCKS expression in 
these cells. To further confirm overexpression of CELF1 directly promotes the 
translation of MARCKS, we quantified MARCKS mRNA levels using qRT-PCR in 
OHKC and OHKC CELF1 overexpressing cells. As expected, we did not observe a 
significant difference in MARCKS mRNA level in OHKC cells relative to OHKC-
CELF1 cells (Figure 14, right panel). Altogether, these two key experimental results 
confirmed that overexpression of CELF1 promotes MARCKS expression at the 
mRNA translational level, but not at the mRNA turnover level.  
Although depletion of CELF1 reduces cell migration in UM74B cells, the 
question remains, whether CELF1 or MARCKS alone or in combination to control 
the function of cell migration. To confirm if MARCKS independently controls cell 
migration in oral cancer cells, we have reduced MARCKS expression in UM74B cells 
using siRNA against MARCKS mRNA (Figure 15, top left panel) and measured cell 
migration using the wound healing assay. As expected, compared to control siRNA 
transfected cells, we observed a 40% decrease in wound closure in MARCKS siRNA 
treated cells (Figure 15, bottom panel), suggesting that MARCKS directly controls 
cell motility in oral cancer cells.  
In addition, to determine if CELF1 controls cell migration through MARCKS, 
we ectopically expressed GFP-tagged MARCKS in CELF1 depleted cells and tested 
whether expression of MARCKS alone enhances or rescues cell migration in oral 
cancer cells. The ectopic expression of MARCKS in CELF1 depleted cells was 
tested by Western blot and is shown in Figure 16, bottom left. Due to severe cell 
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death after CELF1 depletion combined with MARCKS overexpression, we were 
unable to perform wound scratch assay. Consequently, we have utilized a transwell 
migration assay to measure cell motility (Figure 16). As expected in CELF1 depleted 
cells, cell migration was reduced in comparison to shRNA control treated cells; 
whereas cells overexpressing GFP-MARCKS in the absence of CELF1 did not 
exhibits a significant change in migration compared to shRNA control treated cells. 
Thus, the data indicate that CELF1 phenotype was rescued. In another word the cell 
migration phenotype was rescued. In conclusion, the results obtained from specific 
aim-2 positively demonstrated that CELF1 controls cell migration through MARCKS 
protein, which was confirmed by gain- and/or loss-of-function studies of CELF1 and 
























Figure12: CELF1 influences cell migration in UM74B cells. Reduction of 
CELF1 reduces cell migration by 54%. Monolayer cells were wounded and 
photographs were taken immediately after wound induction and 24 hours 
later. The scratch creation was performed as described in materials and 
methods. Additionally, the quantification of wound closer was measured 
using ImageJ software, the protocol is descried in methods and materials 











Figure 13: Overexpression of CELF1 in non-malignant human oral 
keratinocytes (OHKC-CELF1). Overexpression of CELF1 in OHKC enhances 
cell migration by 49% in compared to OHKC. Monolayer cells were wounded 
and photographs were taken immediately after wound induction and 24 hours 
post wound creation. The scratch creation and quantification of wound closer 
protocols are described in methods and materials. Additionally, the 

















Figure 14, left:  Overexpression of CELF1 in OHKC CELF1 Flag tag leads to upregulation of 
MARCKS protein expression. The Western blot of total protein was extracted from OHKC cells 
and OHKC CELF1-Flag tag cells. The CELF1 is overexpressed in the OHKC CELF-Flag tag 
cell line in comparison to OHKC. Additionally, the western blot also shows overexpression of 
MARCKS in OHKC CELF1-Flag tag cells in comparison to OHKC cells.   
Figure 14, right: MARCKS mRNA levels remain unchanged in CELF1 overexpressing OHKC 



















Figure 15: MARCKS influences OSCC cell migration in a scratch wound healing 
assay. Treatment of siRNA against MARCKS reduces cell migration by 40% in 
UM74B. Monolayer of cells were wounded and photographs were taken 
immediately after wound induction and 24 hours post wound creation. The scratch 
creation and quantification of wound closer protocols are described in methods and 
materials. Additionally, the quantification of scratch wound healing assay was 
measured by ImageJ software. N=3, *p<0.0005. 
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Figure 16, top panel: Transwell migration assay of MARCKS overexpression in CELF1 
depleted UM74B cells. 
Figure 16, bottom left panel: Confirmation of overexpression of MARCKS in CELF1 depleted 
UM74B cells. 
Figure 16, bottom right panel: Migration through transwell in UM74B. Migration was 
performed as described in methods and materials. The  N=3; shControl-GFP/ shCELF 1- GFP, 
*p<0.002; shCELF1-GFP/ shCELF-MARCKS, *p<0.025; shContro-GFP;shCELF1-MARCKS; 





 RNA-binding proteins regulate gene expression in mammalian cells mostly at a 
global level through coordinated gene network and control over several cell 
biological processes. For example, systems-level mRNA:protein (mRNP)  biology 
has begun to emerge from quantitative genomic, proteomic, and microscopy-based 
investigations (193). These approaches have yielded information about mRNA and 
protein state, protein-protein, protein-nucleic acid interactions, protein localization, 
and dynamics of mRNP systems and processes. Although large-scale proteomic 
studies have generally focused on whole proteome interactions rather than those of 
mRNP systems in particular, our approach in this thesis primarily focuses on 
proteomic and functional investigation of CELF1 in gene expression and cell 
migration in oral cancer cells.   
 Interestingly, published network analysis of CELF1 and its associated targets in 
cervical cancer cells (HeLa) showed genes that are specifically involved in cell 
migration (194). However, biological studies associated with this observation is 
reported. Based on our pSILAC analysis, we have identified several proteins 
targeted by CELF1 implicated for their role in cell migration and motility. Based on 
our identification of key proteins involved in cell migration, MARCKS becomes a 
prominent protein shown to be associated with cell migration in a variety of cell 
systems (177). Thus, CELF1 associated proteome network analysis followed by 
target validation for functional studies of MARCKS suggest that the systems 
approach on understanding biological function of CELF1 can be very successful.    
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 The results obtained in specific aim-2, for example, depletion of CELF1 
reduces cell migration (Figure 12) and overexpression of CELF1 in non-malignant 
cells enhances cell migration (Figure 13), clearly demonstrate that CELF1 is a 
critical regulator of cell motility. RBPs are well-known for controlling cell migration in 
variety of other systems, for example, HuR has been shown in HeLa cells to stabilize 
the β-actin mRNA by associating with a uridine-rich element within its 3ʹ′ UTR and 
controlling cell adhesion, invasion and migration (195). Thus, our data in-line with 
the above mentioned report and suggest that CELF1’s control of MARCKS could be 
part of the regulatory mechanisms responsible for cell migration in oral cancer cells.  
 MARCKS is a well-known protein factor involved in cell migration that is 
regulated by several different cellular pathways, such as epigenetic modifications, 
transcription and signaling pathways. It is very interesting to add an additional layer 
of regulation for MARCKS through mRNA translation machinery, which controls its 
expression in cancer cells. Based on the findings in this thesis, we are first to report 
that MARCKS is controlled at the mRNA translational level in cancer cells.  
It is interesting to note that we have previously reported that depletion of 
CELF1 in UM74B cells leads to reduction of cell growth and increased apoptosis 
(185). But, specific deletion of CELF1 in OHKC did not alter cell growth or apoptosis 
(57) suggesting that CELF1 function are cancer cell-specific and in cancer cells the 
function of CELF1 is different than normal cells. But overexpression of CELF1 in 
OHKC cells promotes cancer like phenotype. Based on the data obtained from our 
study (Figure 14), we were able to establish that overexpression of CELF1 in non-
malignant cells promotes the expression of MARCKS and subsequently enhances 
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cell motility. Thus, CELF1 and its associated gene network are important regulators 
of cell migration in oral cancer cells.  
It is widely accepted that signal transduction pathways affect cancer cell 
motility through phosphorylation of targeted proteins. For example, PDGF-BB is a 
known mitogen and chemoattractant for fibroblasts that signals through tyrosine 
kinases and the PDGF-BB receptor (PDGFR-BB). PDGF-BB signaling results in 
increased intracellular Ca2+ concentrations and subsequent activation of protein 
kinase C (PKCε), which phosphorylates MARCKS (196, 197). The resulting 
phosphorylated MARCKS is unable to bind with actin filaments and cell migration is 
induced. Thus, kinase activation plays a critical role in MARCKS cell migratory 
activity. Surprisingly, CELF1 was shown to be phosphorylated upon activation of 
PKC (79), which could impact the binding and promotion of MARCKS expression in 
oral cancer cells. Both CELF1 and MARCKS proteins were overexpressed in oral 
cancer cells (Figure 3), and possibly phosphorylated by PKC, but this proposed 
model requires further investigation. It would it interesting to see if activation and 
inactivation of PKC can increase and decrease cell migration through 
















































 Post-transcriptional regulation of gene expression plays an important role in 
disease progression. RNA binding proteins with the help of other accessory proteins 
and mRNAs are capable of regulating multiple steps within the post-transcriptional 
regulatory process. CELF1, a member of CELF family RBPs is known to regulate 
pre-mRNA splicing, mRNA degradation, and mRNA translation (61, 184). CELF1’s 
role in cancer has emerged within the last five years; however, its precise cancer 
biological function has not been established.  Here, we have utilized a global 
proteome-wide analysis and identified the protein MARCKS as a target of CELF1. 
We have also established that cell migration is controlled by CELF1 through 
translational regulation of MARCKS in oral cancer cells.   
Our proteome-wide analysis revealed that approximately 1350 proteins are 
translationally controlled by CELF1. The biological enrichment of these proteins 
discovered a vast variety of genes that are controlled by CELF1 including RNA 
transport, mRNA 3ʹ′ end processing, translation initiation, and cytoskeleton 
remodeling. Moreover, based on statistical analysis of top altered proteins in the 
absence of CELF1, we were able to identify the top 18 genes that were associated 
with CELF1 (Table. 1). Continued analysis of identified genes through KEGG 
pathway, USCS genome browser database and multiple rounds of polysome 
fractionation gradient analysis, we found that MARCKS was a target of CELF1. 
Given the significance of MARCKS role in cell migration, we have identified that 
overexpression of CELF1 controls cell motility in oral cancer cells through regulation 




  In this thesis, we have demonstrated that CELF1 and MARCKS are 
overexpressed in multiple oral cancer cells. Furthermore, we have observed upon 
depletion of CELF1, protein expression of MARCKS is significantly reduced. Using 
RNA-IP we were able to establish CELF1 is directly associated with MARCKS 
mRNA and controls its translation. However, we have not demonstrated the exact 
molecular mechanism of how CELF1 binds to MARCKS mRNA. However, we have 
observed that the MARCKS 3ʹ′ UTR contains canonical GRE sequences, where 
CELF1 can bind and potentially regulate its translation. At the same time, we cannot 
disregard the 5ʹ′ UTR of MARCKS, which contains GU stretches that can also be 
controlled by CELF1. Therefore, future experiments are needed to determine how 
CELF1 control MARCKS translation through association with 5ʹ′ or 3ʹ′ UTRs. To 
address this, we plan to use a luciferase reporters constructs with MARCKS 3ʹ′ or 5ʹ′ 
UTRs to test the expression level of these constructs by the gain- and loss-of-
function of CELF1. This experiment will provide additional confirmation of CELF1’s 
control over MARCKS expression in oral cancer cells and may be suitable for other 
cell systems.   
Conclusion: 
 Overall, the work presented in this thesis has further strengthened our 
understanding of CELF1 function at the post-transcriptional gene regulation level 
and establishes the molecular mechanism of mRNA translation of MARCKS. We 
were able to provide evidence to support MARCKS as a target of CELF1-regulated 
post-transcriptional regulation. Furthermore, in specific aim-2, we were able to 
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demonstrate that CELF1 controls cell migration through MARCKS in oral cancer 
cells. Interestingly, reduction of CELF1 in oral cancer cells down-regulates protein 
synthesis of MARCKS, but not the MARCKS mRNA, further validating that CELF1 is 
controlling MARCKS at the mRNA translational level. Finally, gain-and loss-of-
function of CELF1 and MARCKS in oral cancer cells demonstrated that both proteins 
play a key role in cell migration. The down-regulation of CELF1 resulted in 
decreased MARCKS gene expression, which in turn resulted in decreased cell 
motility of oral cancer cells. Thus, based on all of the data presented in this thesis, 
we conclude that CELF1 mediated cell migration occurs through the post-
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